BioInvent Reports Positive Clinical Trial Data for Ovarian Cancer Treatment

BioInvent International AB released updated clinical study data for its BI-1808 antibody combined with KEYTRUDA® in patients with advanced platinum-resistant ovarian cancer. The study showed a 24% objective response rate and 53% disease control rate in 34 evaluable patients, with responses lasting over 10 months for some. This suggests durable efficacy and good tolerability for the combination therapy in a difficult-to-treat patient population.